Sanofi announced FDA approval of an updated Soliqua label to expand its indication to patients uncontrolled on OADs. Additionally, Soliqua stability has been extended from 14 days to 28 days (vs. 21 days for Novo’s Xultophy). Below, FENIX provides thoughts on how Sanofi will likely leverage the updated Soliqua indiction to position Soliqua as the first injectable as well as increasing Sanofi’s competitive position vs. Xultophy and Basaglar.